Stirling, Scotland, 13 October 2016 (Business Wire) – eClinicalHealth Limited, a cloud-based eClinical technology company, has announced that Kai Langel, co-founder of eClinicalHealth and director of the company’s patient solutions, will speak at the National Institute of Allergy and Infectious Diseases’ 2016 Bioinformatics & Computational Biosciences Festival.
Langel will discuss the “Remote Clinical Research Model – Key Considerations, Methodologies and Results” at 9:45 a.m., Friday, Oct. 21, at the conference in Bethesda, Md.
Langel will discuss the design and results of the VERKKO online Phase IV clinical trial for diabetes, which was conducted completely remotely without any site visits. Data captured during the trial was available in real time to the virtual study site. This innovative trial model employed the Clinpal platform to inform remote patients of their progress, empowering them to manage their own compliance, which resulted in increased compliance and faster completion of the study while reducing the effort required by the virtual site.
The company’s research on remote trial methodologies and patient engagement is helping the pharmaceutical industry address critical challenges. This work has illustrated the importance of fulfilling patient recruitment requirements and designing patient-centric clinical trials.
The NIAID event will bring together industry leaders from government agencies, academia and the private sector to examine how virtual clinical trials are transforming the typical controlled study model and also to discuss how to further clinical research and patient care.
For information about eClinicalHealth’s comprehensive end-to-end cloud platform for patient recruitment, engagement and data capture through direct, patient-facing web solutions, visit eClinicalHealth Limited.
Headquartered in Scotland, eClinicalHealth Limited, developers of the revolutionary Clinpal patient engagement platform, was founded in early 2012 to provide innovative clinical trial solutions. The company is committed to leading open and collaborative innovation discussions about patient-centric clinical trial processes and technology with pharmaceutical companies, CROs and other service and technology providers.